title: [Heparanase and vascular endothelial growth factor expression in non-small-cell lung cancer].
abstract: OBJECTIVE
  To study the clinicopathological significance of heparanase and VEGF expression in NSCLC.
  
  
  METHODS
  Eighty-five lung samples were studied. Each sample was divided into two parts, one used for heparanase mRNA detection by reverse transcription PCR and the other for VEGF detection by immunohistochemistry.
  
  
  RESULTS
  (1) The expressions of heparanase mRNA and VEGF were higher in NSCLC than in benign pulmonary diseases (P < 0.05). (2) The expression of heparanase mRNA was higher in cases with lymph-node invasion, metastasis, stage III and IV diseases, low-differentiation, and adenocarcinoma, as compared to cases without lymph-node invasion and metastasis, with stage I and II diseases, higher and moderate differentiation, and squamous cell cancer (P < 0.05). Its expression was higher in tumors larger than 5 cm in size (P < 0.05). (3) The expression of VEGF was higher in cases with lymph-node invasion, metastasis, and stage III and IV disease, as compared to cases without lymph-node invasion and metastasis, and with stage I and II diseases (P < 0.05). (4) There was no significant correlation between heparanase and VEGF expression (P > 0.05).
  
  
  CONCLUSIONS
  Heparanase and VEGF are associated with NSCLC invasion and metastasis, and may be used to evaluate NSCLC metastasis status. Heparanase and VEGF promote NSCLC invasion and metastasis by independent mechanisms. Detection of these two markers may improve the sensitivity and specificity of the measurement of NSCLC metastatic potential.
authors.affiliation: Department of Thoracic Surgery, Henan Chest Hospital, Zhengzhou 450003, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Gao
authors.forename: Qing-zheng
authors.initials: QZ
authors.lastname: Liang
authors.forename: Xue-qiang
authors.initials: XQ
authors.lastname: Wu
authors.forename: Sui-ying
authors.initials: SY
authors.lastname: Li
authors.forename: Han-lin
authors.initials: HL
authors.lastname: Bai
authors.forename: Shu-lin
authors.initials: SL
authors.lastname: Zhang
authors.forename: Min-xian
authors.initials: MX
authors.lastname: Qi
authors.forename: Wu-ying
authors.initials: WY
authors.lastname: Yuan
authors.forename: Jian-wei
authors.initials: JW
authors.lastname: Wang
authors.forename: Guo-bin
authors.initials: GB
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000556:secondary; D016228:Endothelial Growth Factors / Q000096:biosynthesis*; D005260:Female; D005966:Glucuronidase / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000099175:Heparanase
chemical_list: D014408:Biomarkers, Tumor; D016228:Endothelial Growth Factors; D005966:Glucuronidase; D012333:RNA, Messenger; D000099175:Heparanase